AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice

AbCellera's experimental menopause drug shows significant reduction in hot flashes in Phase 2 trial, shares surge 40%

AbCellera Biologics reported that its non-hormonal menopause treatment ABCL-635 significantly reduced the frequency and severity of hot flashes in a 92-person Phase 2 trial, with the drug meeting both primary endpoints after four weeks. The results sent the company's shares surging nearly 40% in early trading.